Phase II Study of Crenolanib (CP-868,596), a Selective and Potent Inhibitor of PDGFR, for the Treatment of Patients With Advanced Gastrointestinal Stromal Tumors With the D842-related Mutations and Deletions, Including the D842V Mutation, in the PDGFRA Gene

Inclusion Criteria

Inclusion Criteria

- Male or female, of any racial or ethnic group

- Age 18 years or older

- Life expectancy of greater than 12 weeks

- Patient able and willing to provide informed consent

- Normal liver function, defined as AST and ALT ≤2.5x ULN, and Total Bilirubin ≤ 2x
ULN.

- Total creatinine ≤ 1.5x ULN

- ECOG Performance Status 0 - 2 (Appendix II)

- Patients must have histologically or cytologically confirmed GIST with a D842-related
mutation or deletion on the PDGFRA gene

- Patients must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded) as
>20 mm with conventional techniques or as >10 mm with spiral CT scan. See Section
10.1.2 for the evaluation of measurable disease.

- Patients must have recovered from any prior therapy and completed the minimum of,
either 5 half-lives of prior therapy or 2 weeks must have elapsed since prior
treatment

Exclusion Criteria

- Patient unable to provide informed consent

- ECOG Performance status > 2

- Any concurrent anticancer therapy, immunotherapy, or hormonal therapy.

- Any other investigational agents taken within 2 weeks of start of study drug or if
study drug will commence within 5 half-lives of prior therapy

- Patients with known or active Hepatitis B or C; liver cirrhosis.

- Patients with active fungal, viral, and bacterial infections

- Positive serum pregnancy test

- Pregnant or lactating women

- Patients on concomitant medications that induce or inhibit CYP3A4 (Appendix III)

- Patients with severe and/or uncontrolled concurrent medical disease that in the
opinion of the investigator could cause unacceptable safety risks or compromise
compliance with the protocol e.g. impairment of gastrointestinal (GI) function, or GI
disease that may significantly alter the absorption of the study drugs